Literature DB >> 8077714

Predictors of survival in patients with AIDS and disseminated Mycobacterium avium complex disease.

C R Horsburgh1, B Metchock, S M Gordon, J A Havlik, J E McGowan, S E Thompson.   

Abstract

Patients with AIDS and disseminated Mycobacterium avium complex disease (DMAC), as defined by the presence of a positive blood culture for MAC, were studied retrospectively to define the natural history of DMAC. All patients had fevers, severe anemia (hematocrit < 26%), or both. Eighty-seven (76%) had signs, symptoms, or laboratory findings related to the gastrointestinal tract, but no distinct syndrome was identified. Sixty-nine patients received antimycobacterial therapy; assignment to therapy was not randomized. In a proportional hazards analysis, shorter survival was associated with higher initial level of mycobacteremia (relative risk [RR], 1.86; 95% confidence interval [CI], 1.49-2.31; P < .001), while administration of antimycobacterial chemotherapy (RR, 0.42; 95% CI, 0.26-0.70; P < .001) and antiretroviral therapy (RR, 0.40; 95% CI, 0.22-0.73; P < .01) had protective effects. Thus, the initial level of mycobacteremia of patients with DMAC may have prognostic value, and administration of antimycobacterial and antiretroviral agents may be associated with prolonged survival.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077714     DOI: 10.1093/infdis/170.3.573

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Survival patterns among HIV+ individuals based on health care utilization.

Authors:  K J Welch; A Morse
Journal:  J Natl Med Assoc       Date:  2001-06       Impact factor: 1.798

Review 2.  Susceptibility testing of Mycobacterium avium complex isolates.

Authors:  L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

3.  Molecular analysis of the gene encoding F420-dependent glucose-6-phosphate dehydrogenase from Mycobacterium smegmatis.

Authors:  E Purwantini; L Daniels
Journal:  J Bacteriol       Date:  1998-04       Impact factor: 3.490

4.  Effects of recombinant granulocyte-colony stimulating factor administration during Mycobacterium avium infection in mice.

Authors:  A S Gonçalves; R Appelberg
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

5.  PCR-hybridization assay for Mycobacterium avium complex: optimization of detection in peripheral blood from humans.

Authors:  G Ferrario; A Gori; A Rossi; L Catozzi; C Molteni; G Marchetti; A Bandera; M C Rossi; A D Esposti; F Franzetti
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

6.  Differential gene expression in mononuclear phagocytes infected with pathogenic and non-pathogenic mycobacteria.

Authors:  J A McGarvey; D Wagner; L E Bermudez
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

7.  Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression.

Authors:  S M Wahl; T Greenwell-Wild; G Peng; H Hale-Donze; T M Doherty; D Mizel; J M Orenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

8.  Use of PCR in detection of Mycobacterium avium complex (MAC) bacteremia: sensitivity of the assay and effect of treatment for MAC infection on concentrations of human immunodeficiency virus in plasma.

Authors:  R R MacGregor; K Dreyer; S Herman; P K Hocknell; L Nghiem; V J Tevere; A L Williams
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

Review 9.  [Disseminated infection with Mycobacterium avium complex (MAC) in HIV infection].

Authors:  G Fätkenheuer; B Salzberger; V Diehl
Journal:  Med Klin (Munich)       Date:  1998-06-15

10.  Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases.

Authors:  Devyani Deshpande; Shashikant Srivastava; Sandirai Musuka; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.